GeneMedicine's proprietary adenovirus platform enables the development of intratumorally and intravenously administered pipeline products that selectively attack and eradicate tumor cells, stimulate antitumor immune responses, and have proven effective as standalone therapies or in combination with current standard of care. Their oncolytic adenovirus offers advantages over competitors, including higher tumor tissue accumulation and lower systemic exposure. GeneMedicine's pipeline can treat a wide range of tumor types, including metastases from colorectal and lung cancer. They have developed a systemic delivery platform for oncolytic viruses to treat metastatic and recurrent cancers in late-stage patients. GeneMedicine's GM-OAd platform results in immunogenic cell death and long-term therapeutic benefits against cancer. They have a highly scalable, low-cost manufacturable platform and a deep portfolio of intellectual property, including patents for effective degradation of tumor extracellular matrix to enhance the intratumoral permeation and distribution of other conventional cancer drugs.